Biodesix Inc (NASDAQ: BDSX) — Perfil da empresa, notícias e dados financeiros
Biodesix provides innovative lung disease diagnostic tests, focusing on improving patient outcomes with advanced technologies.
Biodesix Inc
Biodesix (NASDAQ:BDSX) is a diagnostic solutions provider committed to guiding and improving patient outcomes through its innovative lung disease diagnostic tests. The company focuses on leveraging advanced technologies, including genomics and proteomics, to discover, develop, and commercialize diagnostic solutions. Their projects primarily target the early detection and treatment of lung diseases, including lung cancer, with a strong emphasis on providing actionable insights that can impact clinical decisions and patient management. Objectives of Biodesix revolve around expanding their diagnostic portfolio, advancing research in lung disease biomarkers, and establishing collaborations to enhance patient care worldwide. Their goal is to transform the landscape of lung disease diagnosis and treatment, making significant impacts on healthcare and patient lives.
Resumo
Operações
Produtos e/ou serviços de Biodesix Inc
- VeriStrat is a proteomic blood test that helps physicians guide treatment for patients with non-small cell lung cancer, providing personalized therapy recommendations.
- GeneStrat is a targeted genomic test that delivers rapid results for actionable mutations in lung cancer patients, aiding in swift and precise treatment decisions.
- The Nodify Lung nodule risk assessment testing suite helps clinicians stratify the risk of lung nodules being malignant, aiding in patient management and care decisions.
- The Blood-based Lung Diagnostic Test provides non-invasive options for detecting lung cancer, utilizing advanced genomic and proteomic technologies for early diagnosis and treatment strategies.
- Bio-Rad SARS-CoV-2 ddPCR Test, developed in collaboration, offers a highly sensitive and accurate tool for detecting COVID-19, contributing to pandemic management and patient care.
- The Immune Profiling Service uses in-depth analysis of the immune system to support pharmaceutical companies in drug development and personalized medicine approaches for cancer treatment.
equipe executiva do Biodesix Inc
- Scott HuttonPresident, CEO & Director
- Robin Harper CowieCFO, Secretary & Treasurer
- Kieran O'KaneChief Commercial Officer
- Heinrich RoderFounder & CTO
- Gary Anthony PestanoChief Scientific Officer
- Jessica OlbrichtSenior Director of Human Resources
- Bobbi CoffinChief Growth Officer
- James R. JettCo-Chief Medical Officer
- Steven C. SpringmeyerCo-Chief Medical Officer
- Michael N. KammerHead of Radiomics
Principais indicadores financeiros
Resultados divulgados pela Biodesix Inc, em USD.
- Cap. de mercado
- 231,6 mi
- Receita (TTM)
- 102,9 mi
- P/L
- —
- LPA (diluído, TTM)
- -3.1
- Dividend yield
- —
- Margem de lucro
- -27.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 88,5 mi | -27,8 mi | -35,3 mi | |
| 71,3 mi | -34,5 mi | -42,9 mi | |
| 49,1 mi | -41,3 mi | -52,1 mi | |
| 38,2 mi | -50,6 mi | -65,4 mi |